益脉康胶囊联合康柏西普治疗视网膜静脉阻塞的临床研究

目的探讨益脉康胶囊联合康柏西普眼用注射液治疗视网膜静脉阻塞的临床疗效。方法选取2019年8月—2020年12月在中国人民武装警察部队河南省总队医院眼科就诊的106例视网膜静脉阻塞患者作为研究对象,所有患者按随机数字表法分为对照组和治疗组,每组各53例。对照组采用无菌针管将康柏西普眼用注射液注入角膜缘后4mm睫状体平坦部位,0.05 mL/次,1次/月,共治疗3次。治疗组在对照组基础上口服益脉康胶囊,0.6 g/次,3次/d。两组在治疗3个月统计疗效。观察两组的临床疗效,评估两组患者治疗前后黄斑中心凹厚度、最佳矫正视力值(BCVA)。检测患者的血清白细胞介素-6(IL-6)、巨噬细胞炎性蛋白-1(MIP-1)、超敏C-反应蛋白(hs-CRP)水平。结果治疗后,治疗组患者的总有效率为94.34%,对照组的总有效率为81.13%,组间有明显差异(P0.05)。治疗后,两组的黄斑中心凹厚度显著降低,BCVA明显升高(P0.05);治疗组的黄斑中心凹厚度比对照组低(P0.05),BCVA比对照组高。治疗后,两组的IL-6、MIP-1、hs-CRP水平显著降低(P0.05),治疗组IL-6、MIP-1、hs-CRP水平降低比对照组明显(P0.05)。结论益脉康胶囊联合康柏西普眼用注射液治疗视网膜静脉阻塞具有较好的临床疗效,可提高视力,减轻炎症反应,不增加不良反应。

Clinical study on Yimaikang Capsules combined with conbercept in treatment of retinal vein occlusion

Objective To investigate the clinical efficacy of Yimaikang Capsules combined with Conbercept Ophthalmic Injection in treatment of retinal vein occlusion. Methods Patients (106 cases) with retinal vein occlusion in Henan Provincial Corps Hospital of Chinese People''s Armed Police Force from August 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were injection administered with Conbercept Ophthalmic Injection at the flat part of the ciliary body 4 mm behind the limbus of cornea, 0.05 mL/time, once monthly. Patients in the treatment group were po administered with Yimaikang Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the macular fovea thickness and BCVA levels of the two groups before and after treatment were evaluated. The serum levels of IL-6, MIP-1, and hs-CRP were detected. Results After treatment, the total effective rate of the treatment group was 94.34%, the total effective rate of the control group was 81.13%, and there was a significant difference between the two groups (P < 0.05). After treatment, the thickness of macular fovea in two groups were significantly decreased, but the BCVA in two groups were significantly increased (P < 0.05). The thickness of macular fovea in the treatment group was lower than that in the control group, but the BCVA in the treatment group was higher than that in the control group (P < 0.05). After treatment, the levels of IL-6, MIP-1, and hs-CRP in two groups were significantly decreased (P < 0.05). The levels of IL-6, MIP-1, and hs-CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Yimaikang Capsules combined with Conbercept Ophthalmic Injection has clinical curative effect in treatment of retinal vein occlusion, can improve vision, reduce inflammatory reaction, without increasing the risk of adverse reactions.